Haemonetics Corporation’s HAE growth in the fiscal second quarter of 2025 can be attributed to the strong potential of the Plasma franchise. The robust uptake of the NexSys PCS system bodes well for ...
Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results